According to information gathered from a new analysis of the Framingham Heart Study, there is not a link between a female’s menopausal age and her chances of developing atrial fibrillation (AF). However, the study’s lead author, Dr. Jared W. Magnani of Boston University School of Medicine, took the time to explain to Reuters Health that the study wasn’t robust enough to prove conclusively that there isn’t a link between menopausal age and AF.

One thing that is evident is that younger women who develop menopause naturally are more likely to suffer from strokes, myocardial infarctions and death, whereas older menopausal age has been linked to a lower chance of women dying from ischemic heart disease. This information was noted by Magnani and his team in the American  back in April.

Magnani said that there are many positive ways that a female’s menopausal age can influence AF, too.

“Women tend to develop hypertension with earlier menopause, and following menopause,” he notes. “There’s also an association with inflammation following menopause, and there are novel inflammation markers, particularly C-reactive protein, which have been related to atrial fibrillation as well.”

Magnani believes that the Framingham study is worth pursuing because during that study, the pathophysiological mechanism could not be measured properly. AF is a condition that causes the heart to beat irregularly or flutter, and can lead to strokes. Drugs like Multaq are often used to treat the condition, but sometimes those drugs cause more harm than good. With Multaq, patients often develop liver failure and a worsening of their heart conditions, which is why the drug is no longer being prescribed unless all other medications prove useless.

If you or a loved one have developed liver failure or a worsening of your heart condition after using Multaq, contact attorney Greg Jones today for a free consultation. I am experienced at fighting Multaq lawsuits and may be able to help you recover money for your injuries.